Drugs / HP 13C Pyruvate
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07510607 | Jun 2026 → Dec 2029 expected | relapsing-remitting multiple sclerosis | Ari Green | Recruiting | No outcome recorded |
| Phase 2 | NCT03952598 | Oct 2019 → Dec 2027 | low grade glioma, malignant glioma | National Cancer Institute (NCI) | Suspended | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HP 13C Pyruvate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03952598 ↗ |
| Modality | Diagnostic / imaging agent | “Contrast agent used with magnetic resonance spectroscopic imaging (MRSI)” NCT03952598 ↗ |
| Route | Intravenous | “injected into a vein” NCT03952598 ↗ |